Compounds > indazole-3-carboxylic acid
Page last updated: 2024-12-07

indazole-3-carboxylic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

indazole-3-carboxylic acid: derivatives of above cpd are often antispermatogenic agents [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID78250
CHEMBL ID502057
SCHEMBL ID42245
MeSH IDM0101262

Synonyms (63)

Synonym
AC-1391
BB 0216340
1h-indazol-3-carbonsäure
z1yol9c0vn ,
ec 224-794-5
einecs 224-794-5
nsc 520610
unii-z1yol9c0vn
smr000020832
1h-indazole-3-carboxylic acid
MLS000085703
nsc-520610
nsc520610
4498-67-3
indazole-3-carboxylic acid
benzopyrazole-3-carboxylic acid
indazole-3-carboxylic acid, >=97.0% (hplc)
STK500651
I0672
3-carboxyindazole
3-indazolecarboxylic acid
ksc-20-082
KUC107413N
F2130-0062
CHEMBL502057
indazole-3-carboxylicacid
AKOS000120223
A7112
HMS2282O09
BP-10770
FT-0601452
FS-2171
AM20040500
PB33857
SCHEMBL42245
SY003148
mfcd00211066
indazole 3-carboxylic acid
1-h-indazole-3-carboxylic acid
indazole3-carboxylic acid
3-indazole carboxylic acid
indazole-3-carboxilic acid
indazol-3-carboxylic acid
AKOS024125459
J-650283
W-106172
DS-0585
1h-indazol-3-carbonic acid
DTXSID10196347
CS-W002518
877309-58-5
2h-indazole-3-carboxylic acid
BCP22889
granisetron intermediates
EN300-21445
SB10368
granisetron hydrochloride imp. h (ep); granisetron imp. h (ep); 1h-indazole-3-carboxylic acid; granisetron hydrochloride impurity h; granisetron impurity h
granisetron hydrochloride impurity h
granisetron ep impurity h
3(1h)-indazolecarboxylic acid
2h-indazole-3-carboxylicacid
HY-W002518
Z104497388
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency28.18380.631035.7641100.0000AID504339
Smad3Homo sapiens (human)Potency3.16230.00527.809829.0929AID588855
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (15)

Assay IDTitleYearJournalArticle
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID388078Inhibition of NOS in Sprague-Dawley rat brain by oxyhaemoglobin assay2008Bioorganic & medicinal chemistry, Oct-01, Volume: 16, Issue:19
Fluorescent polycyclic ligands for nitric oxide synthase (NOS) inhibition.
AID1494470Inhibition of Rickettsia prowazekii N-terminal His6-tagged methionine aminopeptidase 1 expressed in Escherichia coli DLB3 Rosetta cells at 10 uM using Met-AMC as substrate preincubated for 1 hr followed by 30 mins incubation after substrate addition measu2018Bioorganic & medicinal chemistry letters, 05-01, Volume: 28, Issue:8
The identification of inhibitory compounds of Rickettsia prowazekii methionine aminopeptidase for antibacterial applications.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (15.38)18.7374
1990's0 (0.00)18.2507
2000's5 (38.46)29.6817
2010's4 (30.77)24.3611
2020's2 (15.38)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 23.46

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index23.46 (24.57)
Research Supply Index2.64 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (23.46)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
betaine
glycine betaine : The amino acid betaine derived from glycine.		2.0510amino-acid betaine;
glycine derivative		fundamental metabolite
pyrazinoic acid
pyrazinoic acid: active metabolite of pyrazinamide; structure. pyrazine-2-carboxylic acid : The parent compound of the class of pyrazinecarboxylic acids, that is pyrazine bearing a single carboxy substituent. The active metabolite of the antitubercular drug pyrazinamide.		2.1710pyrazinecarboxylic acidantitubercular agent;
drug metabolite
7-nitroindazole
7-nitroindazole: an inhibitor of nitric oxide synthase; exhibits anti-nociceptive activity without increasing blood pressure		2.0410
pimagedine
pimagedine: diamine oxidase & nitric oxide synthase inhibitor; an advanced glycosylation end product inhibitor; used in the treatment of diabetic complications; structure. aminoguanidine : A one-carbon compound whose unique structure renders it capable of acting as a derivative of hydrazine, guanidine or formamide.		2.0410guanidines;
one-carbon compound		EC 1.14.13.39 (nitric oxide synthase) inhibitor;
EC 1.4.3.4 (monoamine oxidase) inhibitor
kynurenic acid
Kynurenic Acid: A broad-spectrum excitatory amino acid antagonist used as a research tool.. kynurenic acid : A quinolinemonocarboxylic acid that is quinoline-2-carboxylic acid substituted by a hydroxy group at C-4.		2.1710monohydroxyquinoline;
quinolinemonocarboxylic acid		G-protein-coupled receptor agonist;
human metabolite;
neuroprotective agent;
nicotinic antagonist;
NMDA receptor antagonist;
Saccharomyces cerevisiae metabolite
tryptophan
Tryptophan: An essential amino acid that is necessary for normal growth in infants and for NITROGEN balance in adults. It is a precursor of INDOLE ALKALOIDS in plants. It is a precursor of SEROTONIN (hence its use as an antidepressant and sleep aid). It can be a precursor to NIACIN, albeit inefficiently, in mammals.. tryptophan : An alpha-amino acid that is alanine bearing an indol-3-yl substituent at position 3.		210erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid zwitterion;
L-alpha-amino acid;
proteinogenic amino acid;
tryptophan zwitterion;
tryptophan		antidepressant;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
anthranilamide
[no description available]		2.1710substituted aniline
indazoles
Indazoles: A group of heterocyclic aromatic organic compounds consisting of the fusion of BENZENE and PYRAZOLES.		3.2560indazole
5-methylpyrazole-3-carboxylic acid
5-methylpyrazole-3-carboxylic acid: structure. 5-methyl-pyrazole-3-carboxylic acid : A memebr of the class of pyrazoles that is 1H-pyrazole with methyl and carboxylic acid group substituents at positions 5 and 3 respectively.		2.1710monocarboxylic acid;
pyrazoles		metabolite
lonidamine
lonidamine: structure. lonidamine : A member of the class of indazoles that is 1H-indazole that is substituted at positions 1 and 3 by 2,4-dichlorobenzyl and carboxy groups, respectively.		2.3920dichlorobenzene;
indazoles;
monocarboxylic acid		antineoplastic agent;
antispermatogenic agent;
EC 2.7.1.1 (hexokinase) inhibitor;
geroprotector
tolnidamine
tolnidamine: structure given in first source		1.9610
2-(2'-pyridyl)benzimidazole
2-(2'-pyridyl)benzimidazole: structure in first source		2.1710
1,2,3,4-tetrahydro-beta-carboline-3-carboxylic acid
1,2,3,4-tetrahydro-beta-carboline-3-carboxylic acid: structure given in first source; RN given refers to cpd without isomeric designation. 1,2,3,4-tetrahydro-beta-carboline-3-carboxylic acid : A member of the class of beta-carbolines that is 1,2,3,4-tetrahydro-beta-carboline substituted at position 3 by a carboxy group.		2.1710alpha-amino acid;
aromatic amino acid;
beta-carboline alkaloid		human urinary metabolite;
human xenobiotic metabolite;
plant metabolite;
rat metabolite
1-p-chlorobenzyl-1h-indazole-3-carboxylic acid
1-p-chlorobenzyl-1H-indazole-3-carboxylic acid: RN given refers to cpd with isomeric designation; structure		1.9610indazoles
tryptophan methyl ester
tryptophan methyl ester: RN given refers to parent cpd(DL)-isomer		210
5-phenyl-3-isoxazolecarboxylic acid
5-phenyl-3-isoxazolecarboxylic acid: RN given refers to parent cpd		2.1710
5-deazariboflavin
5-deazariboflavin: deaza analog of riboflavin used to elucidate chemical role of the flavin coenzyme; structure		210
4-quinolone-3-carboxylic acid
4-quinolone-3-carboxylic acid: structure in first source		2.1710
riboflavin
vitamin B2 : Any member of a group of vitamers that belong to the chemical structural class called flavins that exhibit biological activity against vitamin B2 deficiency. Symptoms associated with vitamin B2 deficiency include glossitis, seborrhea, angular stomaitis, cheilosis and photophobia. The vitamers include riboflavin and its phosphate derivatives (and includes their salt, ionised and hydrate forms).		210flavin;
vitamin B2		anti-inflammatory agent;
antioxidant;
cofactor;
Escherichia coli metabolite;
food colouring;
fundamental metabolite;
human urinary metabolite;
mouse metabolite;
photosensitizing agent;
plant metabolite
flavin-adenine dinucleotide
Flavin-Adenine Dinucleotide: A condensation product of riboflavin and adenosine diphosphate. The coenzyme of various aerobic dehydrogenases, e.g., D-amino acid oxidase and L-amino acid oxidase. (Lehninger, Principles of Biochemistry, 1982, p972)		210flavin adenine dinucleotide;
vitamin B2		cofactor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
prosthetic group
2-(3-carboxy-2-pyridinyl)-3-pyridinecarboxylic acid
[no description available]		2.1710bipyridines
3-ethyl-5-methyl-4-oxo-6-thieno[2,3-d]pyrimidinecarboxylic acid
[no description available]		2.1710organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound
3-chloro-6-(3,5-dimethyl-1h-pyrazol-1-yl)picolinic acid
3-chloro-6-(3,5-dimethyl-1H-pyrazol-1-yl)picolinic acid: structure in first source		2.1710
1-(4-methylphenyl)-3-(1H-1,2,4-triazol-5-ylthio)pyrrolidine-2,5-dione
[no description available]		2.1710pyrrolidines
5-tert-butyl-4,5,6,7-tetrahydro-1H-indazole-3-carboxylic acid
[no description available]		2.1710pyrazoles
ConditionIndicatedRelationship StrengthStudiesTrials
Degenerative Diseases, Central Nervous System
[description not available]		02.0410
Neurodegenerative Diseases
Hereditary and sporadic conditions which are characterized by progressive nervous system dysfunction. These disorders are often associated with atrophy of the affected central or peripheral nervous system structures.		02.0410
Innate Inflammatory Response
[description not available]		02.0510
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.0510
Adenocarcinoma, Basal Cell
[description not available]		02.0410
Cancer of Colon
[description not available]		02.0410
Adenocarcinoma
A malignant epithelial tumor with a glandular organization.		02.0410
Colonic Neoplasms
Tumors or cancer of the COLON.		02.0410
Fetal Death
Death of the developing young in utero. BIRTH of a dead FETUS is STILLBIRTH.		01.9610
Experimental Neoplasms
[description not available]		01.9610
Pregnancy
The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.		01.9610